{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:03:26Z","timestamp":1788537806448,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K08771"],"award-info":[{"award-number":["22K08771"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K08771"],"award-info":[{"award-number":["22K08771"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2025,10,5]]},"DOI":"10.1038\/s41416-025-03087-1","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T16:11:39Z","timestamp":1752595899000},"page":"771-783","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["High expression of the cachexia-related protein Fn14 in esophageal squamous cell carcinoma correlates with poor chemotherapy response and anti-Fn14 therapy decreases chemotherapeutic resistance"],"prefix":"10.1038","volume":"133","author":[{"given":"Kei","family":"Adachi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Kamakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Momose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1733-5064","authenticated-orcid":false,"given":"Takuro","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7918-4217","authenticated-orcid":false,"given":"Tomoki","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2397-1478","authenticated-orcid":false,"given":"Tsuyoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2883-0132","authenticated-orcid":false,"given":"Yukinori","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyokazu","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"3087_CR1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489\u201395.","journal-title":"Lancet Oncol"},{"key":"3087_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/jcp.26811","volume":"234","author":"SI Daas","year":"2018","unstructured":"Daas SI, Rizeq BR, Nasrallah GK. Adipose tissue dysfunction in cancer cachexia. J Cell Physiol. 2018;234:13\u201322.","journal-title":"J Cell Physiol"},{"key":"3087_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.597675","volume":"11","author":"JM Webster","year":"2020","unstructured":"Webster JM, Kempen L, Hardy RS, Langen RCJ. Inflammation and skeletal muscle wasting during cachexia. Front Physiol. 2020;11:597675.","journal-title":"Front Physiol"},{"key":"3087_CR4","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1038\/sj.bjc.6601781","volume":"90","author":"PJ Ross","year":"2004","unstructured":"Ross PJ, Ashley S, Norton A, Priest K, Waters JS, Eisen T, et al. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer. 2004;90:1905\u201311.","journal-title":"Br J Cancer"},{"key":"3087_CR5","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/ags3.12669","volume":"7","author":"N Keigo","year":"2023","unstructured":"Keigo N, Koichiro H, Teppei K, Junji T, Yuichi N, Hironori O, et al. Usefulness of the cachexia index as a prognostic indicator for patients with gastric cancer. Ann Gastroenterol Surg. 2023;7:733\u201340.","journal-title":"Ann Gastroenterol Surg"},{"key":"3087_CR6","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"3087_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.105","volume":"4","author":"VE Baracos","year":"2018","unstructured":"Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia. Nat Rev Dis Primers. 2018;4:17105.","journal-title":"Nat Rev Dis Primers"},{"key":"3087_CR8","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/ags3.12603","volume":"6","author":"O Junya","year":"2022","unstructured":"Junya O, Soji O, Koshiro I, Hiroyuki D. Clinical significance of sarcopenic dysphagia for patients with esophageal cancer undergoing esophagectomy: a review. Ann Gastroenterol Surg. 2022;6:738\u201345.","journal-title":"Ann Gastroenterol Surg"},{"key":"3087_CR9","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S1470-2045(11)70142-5","volume":"12","author":"KM Sjoquist","year":"2011","unstructured":"Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681\u201392.","journal-title":"Lancet Oncol"},{"key":"3087_CR10","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1002\/cncr.24390","volume":"115","author":"H Miyata","year":"2009","unstructured":"Miyata H, Yoshioka A, Yamasaki M, Nushijima Y, Takiguchi S, Fujiwara Y, et al. Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy. Cancer. 2009;115:3324\u201334.","journal-title":"Cancer"},{"key":"3087_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10388-018-0641-9","volume":"16","author":"Y Kitagawa","year":"2019","unstructured":"Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, et al. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus. 2019;16:1\u201324.","journal-title":"Esophagus"},{"key":"3087_CR12","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","volume":"17","author":"JS Temel","year":"2016","unstructured":"Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016;17:519\u201331.","journal-title":"Lancet Oncol"},{"key":"3087_CR13","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1093\/annonc\/mdx192","volume":"28","author":"D Currow","year":"2017","unstructured":"Currow D, Temel JS, Abernethy A, Milanowski J, Friend J, Fearon KC. ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. Ann Oncol. 2017;28:1949\u201356.","journal-title":"Ann Oncol"},{"key":"3087_CR14","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1002\/cncr.32406","volume":"125","author":"S Hamauchi","year":"2019","unstructured":"Hamauchi S, Furuse J, Takano T, Munemoto Y, Furuya K, Baba H, et al. A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. Cancer. 2019;125:4294\u2013302.","journal-title":"Cancer"},{"key":"3087_CR15","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/cncr.31128","volume":"124","author":"N Katakami","year":"2018","unstructured":"Katakami N, Uchino J, Yokoyama T, Naito T, Kondo M, Yamada K, et al. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer. 2018;124:606\u201316.","journal-title":"Cancer"},{"key":"3087_CR16","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.cell.2015.08.031","volume":"162","author":"AJ Johnston","year":"2015","unstructured":"Johnston AJ, Murphy KT, Jenkinson L, Laine D, Emmrich K, Faou P, et al. Targeting of Fn14 prevents cancer-induced cachexia and prolongs survival. Cell. 2015;162:1365\u201378.","journal-title":"Cell"},{"key":"3087_CR17","doi-asserted-by":"publisher","first-page":"13455","DOI":"10.1074\/jbc.M112.435917","volume":"288","author":"S Salzmann","year":"2013","unstructured":"Salzmann S, Seher A, Trebing J, Weisenberger D, Rosenthal A, Siegmund D, et al. Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity. J Biol Chem. 2013;288:13455\u201366.","journal-title":"J Biol Chem"},{"key":"3087_CR18","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.cell.2007.10.030","volume":"131","author":"E Varfolomeev","year":"2007","unstructured":"Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell. 2007;131:669\u201381.","journal-title":"Cell"},{"key":"3087_CR19","doi-asserted-by":"publisher","first-page":"ra22","DOI":"10.1126\/scisignal.2001878","volume":"5","author":"E Varfolomeev","year":"2012","unstructured":"Varfolomeev E, Goncharov T, Maecker H, Zobel K, Komuves LG, Deshayes K, et al. Cellular inhibitors of apoptosis are global regulators of NF-kappaB and MAPK activation by members of the TNF family of receptors. Sci Signal. 2012;5:ra22.","journal-title":"Sci Signal"},{"key":"3087_CR20","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1038\/sj.cdd.4402027","volume":"13","author":"JE Vince","year":"2006","unstructured":"Vince JE, Silke J. TWEAK shall inherit the earth. Cell Death Differ. 2006;13:1842\u20134.","journal-title":"Cell Death Differ"},{"key":"3087_CR21","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3389\/fonc.2020.00439","volume":"10","author":"L Liang","year":"2020","unstructured":"Liang L, Cheng C, Hu G, Wang X, Liu J, Yan Z, et al. TWEAK promotes the proliferation of squamous cell carcinoma cells through activating cIAP1 signals. Front Oncol. 2020;10:439.","journal-title":"Front Oncol"},{"key":"3087_CR22","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/annonc\/mdw439","volume":"28","author":"M Yamasaki","year":"2017","unstructured":"Yamasaki M, Yasuda T, Yano M, Hirao M, Kobayashi K, Fujitani K, et al. Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003). Ann Oncol. 2017;28:116\u201320.","journal-title":"Ann Oncol"},{"key":"3087_CR23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/ags3.12388","volume":"5","author":"K Sugimura","year":"2021","unstructured":"Sugimura K, Yamasaki M, Yasuda T, Yano M, Hirao M, Fujitani K, et al. Long-term results of a randomized controlled trial comparing neoadjuvant Adriamycin, cisplatin, and 5-fluorouracil vs docetaxel, cisplatin, and 5-fluorouracil followed by surgery for esophageal cancer (OGSG1003). Ann Gastroenterol Surg. 2021;5:75\u201382.","journal-title":"Ann Gastroenterol Surg"},{"key":"3087_CR24","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1158\/1541-7786.MCR-08-0005","volume":"6","author":"AL Willis","year":"2008","unstructured":"Willis AL, Tran NL, Chatigny JM, Charlton N, Vu H, Brown SA, et al. The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity. Mol Cancer Res. 2008;6:725\u201334.","journal-title":"Mol Cancer Res"},{"key":"3087_CR25","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/S0002-9440(10)63927-2","volume":"162","author":"NL Tran","year":"2003","unstructured":"Tran NL, McDonough WS, Donohue PJ, Winkles JA, Berens TJ, Ross KR, et al. The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am J Pathol. 2003;162:1313\u201321.","journal-title":"Am J Pathol"},{"key":"3087_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.695533","volume":"9","author":"L Aye","year":"2021","unstructured":"Aye L, Song X, Yang J, Hu L, Sun X, Zhou J, et al. Identification of a costimulatory molecule gene signature to predict survival and immunotherapy response in head and neck squamous cell carcinoma. Front Cell Dev Biol. 2021;9:695533.","journal-title":"Front Cell Dev Biol"},{"key":"3087_CR27","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.7314\/APJCP.2013.14.6.3509","volume":"14","author":"N Li","year":"2013","unstructured":"Li N, Hu WJ, Shi J, Xue J, Guo WX, Zhang Y, et al. Roles of fibroblast growth factor-inducible 14 in hepatocellular carcinoma. Asian Pac J Cancer Prev. 2013;14:3509\u201314.","journal-title":"Asian Pac J Cancer Prev"},{"key":"3087_CR28","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1097\/CAD.0000000000000153","volume":"25","author":"X Li","year":"2014","unstructured":"Li X, Zhu W, Chen Z, Luo L, Huang J, Zhang F, et al. Fibroblast growth factor-inducible 14 regulates cell growth and multidrug resistance of small-cell lung cancer through the nuclear factor-kappaB pathway. Anticancer Drugs. 2014;25:1152\u201364.","journal-title":"Anticancer Drugs"},{"key":"3087_CR29","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/neuonc\/noy063","volume":"20","author":"DS Hersh","year":"2018","unstructured":"Hersh DS, Harder BG, Roos A, Peng S, Heath JE, Legesse T, et al. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance. Neuro Oncol. 2018;20:1321\u201330.","journal-title":"Neuro Oncol"},{"key":"3087_CR30","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3892\/ijo.2013.2211","volume":"44","author":"OH Kwon","year":"2014","unstructured":"Kwon OH, Kim JH, Kim SY, Kim YS. TWEAK\/Fn14 signaling mediates gastric cancer cell resistance to 5-fluorouracil via NF-\u03baB activation. Int J Oncol. 2014;44:583\u201390.","journal-title":"Int J Oncol."},{"key":"3087_CR31","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/7410","volume":"5","author":"CY Wang","year":"1999","unstructured":"Wang CY, Cusack JC Jr, Liu R, Baldwin AS Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med. 1999;5:412\u20137.","journal-title":"Nat Med"},{"key":"3087_CR32","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.cell.2011.02.023","volume":"145","author":"S Biton","year":"2011","unstructured":"Biton S, Ashkenazi A. NEMO and RIP1 control cell fate in response to extensive DNA damage via TNF-a feedforward signaling. Cell. 2011;145:92\u2013103.","journal-title":"Cell"},{"key":"3087_CR33","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1158\/1541-7786.MCR-13-0458","volume":"12","author":"TG Whitsett","year":"2014","unstructured":"Whitsett TG, Mathews IT, Cardone MH, Lena RJ, Pierceall WE, Bittner M, et al. Mcl-1 mediates TWEAK\/Fn14-induced non-small cell lung cancer survival and therapeutic response. Mol Cancer Res. 2014;12:550\u20139.","journal-title":"Mol Cancer Res"},{"key":"3087_CR34","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1158\/1535-7163.MCT-17-0330","volume":"17","author":"ET Lam","year":"2018","unstructured":"Lam ET, Eckhardt SG, Messersmith W, Jimeno A, O\u2019Bryant CL, Ramanathan RK, et al. Phase I study of enavatuzumab, a first-in-class humanized monoclonal antibody targeting the TWEAK receptor, in patients with advanced solid tumors. Mol Cancer Ther. 2018;17:215\u201321.","journal-title":"Mol Cancer Ther"},{"key":"3087_CR35","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.cell.2005.09.022","volume":"123","author":"H Maecker","year":"2005","unstructured":"Maecker H, Varfolomeev E, Kischkel F, Lawrence D, LeBlanc H, Lee W, et al. TWEAK attenuates the transition from innate to adaptive immunity. Cell. 2005;123:931\u201344.","journal-title":"Cell"},{"key":"3087_CR36","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41416-018-0363-8","volume":"120","author":"C Liu","year":"2019","unstructured":"Liu C, He H, Li X, Su MA, Cao Y. Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy. Br J Cancer. 2019;120:346\u201355.","journal-title":"Br J Cancer"},{"key":"3087_CR37","doi-asserted-by":"publisher","first-page":"32401","DOI":"10.1074\/jbc.272.51.32401","volume":"272","author":"Y Chicheportiche","year":"1997","unstructured":"Chicheportiche Y, Bourdon P, Xu H, Hsu Y, Scott H, Hession C, et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem. 1997;272:32401\u201310.","journal-title":"J Biol Chem"},{"key":"3087_CR38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0968-0004(01)01995-8","volume":"27","author":"JL Bodmer","year":"2002","unstructured":"Bodmer JL, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci. 2002;27:19\u201326.","journal-title":"Trends Biochem Sci"},{"key":"3087_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.935086","volume":"13","author":"O Zaitseva","year":"2022","unstructured":"Zaitseva O, Hoffmann A, Otto C, Wajant H. Targeting fibroblast growth factor (FGF)-inducible 14 (Fn14) for tumor therapy. Front Pharmacol. 2022;13:935086.","journal-title":"Front Pharmacol"},{"key":"3087_CR40","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1007\/s00018-020-03495-x","volume":"77","author":"AL Pascoe","year":"2020","unstructured":"Pascoe AL, Johnston AJ, Murphy RM. Controversies in TWEAK-Fn14 signaling in skeletal muscle atrophy and regeneration. Cell Mol Life Sci. 2020;77:3369\u201381.","journal-title":"Cell Mol Life Sci"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03087-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03087-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03087-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T09:53:32Z","timestamp":1758275612000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03087-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,10,5]]}},"alternative-id":["3087"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03087-1","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"28 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study had a retrospective design and was approved by the Institutional Ethics Review Committee of Certificate Number 08226-10. All the procedures were performed in accordance with the principles of the Declaration of Helsinki and its amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of these data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}